Pierre Vande Perre

Dr. Pierre Vande Perre

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2018 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
PPP. Pujol
P. Pujol
PPPierre Vande Perre
Pierre Vande Perre
LFLaurence Faivre
Laurence Faivre
DSDamien Sanlaville
Damien Sanlaville
CCCarole Corsini
Carole Corsini
DGDavid Geneviève
David Geneviève
In oncology, the expanding use of multi-gene panels to explore familial cancer predisposition and tumor genome analysis has led to increased secondary findings discoveries (SFs) and has given rise to important medical, ethical, and legal issues. The American College of Medical Genetics and Genomics published a policy statement for managing SFs for a list of genes, including 25 cancer-related genes. Currently, there are few recommendations in Europe. From June 2016 to May 2017, the French Society of Predictive and Personalized Medicine (SFMPP) established a working group of 47 experts to elaborate guidelines for managing information given on the SFs for genes related to cancers. A subgroup of ethicists, lawyers, patients’ representatives, and psychologists provided ethical reflection, information guidelines, and materials (written consent form and video). A subgroup with medical expertise, including oncologists and clinical and molecular geneticists, provided independent evaluation and classification of 60 genes. The main criteria were the “actionability” of the genes (available screening or prevention strategies), the risk evaluation (severity, penetrance, and age of disease onset), and the level of evidence from published data. Genes were divided into three classes: for class 1 genes (n = 36), delivering the information on SFs was recommended; for class 2 genes (n = 5), delivering the information remained questionable because of insufficient data from the literature and/or level of evidence; and for class 3 genes (n = 19), delivering the information on SFs was not recommended. These guidelines for managing SFs for cancer-predisposing genes provide new insights for clinicians and laboratories to standardize clinical practices.

27 October 2018 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
PPPierre Vande Perre
Pierre Vande Perre
ASA. Siegfried
A. Siegfried
CCC. Corsini
C. Corsini
DBD. Bonnet
D. Bonnet
CTC. Toulas
C. Toulas
RGR. Guimbaud
R. Guimbaud

1 June 2019 in Psycho-Oncology
Verified
Journal Article
Closed access
PDF file
NANathalie Alegre
Nathalie Alegre
PPPierre Vande Perre
Pierre Vande Perre
YBYves Jean Bignon
Yves Jean Bignon
AMAude Michel
Aude Michel
VGVirginie Galibert
Virginie Galibert
PPP. Pujol
P. Pujol

11 October 2018 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
PPPierre Vande Perre
Pierre Vande Perre
DTDaniel Toledano
Daniel Toledano
CCCarole Corsini
Carole Corsini
EEElsa Escriba
Elsa Escriba
MLMarine Laporte
Marine Laporte
PPP. Pujol
P. Pujol
Background: General practitioners (GPs) have an increasing role in referring patients with putative mutation in BRCA1/2 genes for genetics consultation and for long‐term follow‐up of mutation carriers.Methods: We compared the expectations of the GPs’ role according to BRCA1/2 mutation carriers and to GPs themselves.Results: Overall, 38% (58/152) of eligible GPs and 70% (176/252) of eligible patients were surveyed. Although 81% of GPs collected the family history, only 24% considered that they know criteria indicating genetics consultation and 39% sufficient knowledge of BRCA1/2 guidelines to answer patients’ questions. Twelve% of GPs were aware of the French national guidelines. Among unsatisfied patients, 40% felt that their GP was able to answer (moderately, sufficiently, or completely) specific questions about BRCA1/2 care as compared with 81% in satisfied patients. Only 33% of GPs reported being informed directly by the geneticist about the patients’ results. GPs’ main expectations for their role in BRCA1/2 carrier care were psychological support and informing relatives about screening (72% and 71%, respectively), which contrasts with the perceptions of patients, who mainly requested medical advice for BRCA1/2‐related care (51%).Conclusion: There is an important need for GP training and enhancing interactions between GPs and geneticists to improve the GP's role in BRCA1/2 screening and management.

1 February 2018 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
PPPierre Vande Perre
Pierre Vande Perre
CSC. Zazo Seco
C. Zazo Seco
OPO. Patat
O. Patat
LBL. Bouneau
L. Bouneau
AVA. Vigouroux
A. Vigouroux
PCP. Calvas
P. Calvas

Verified
Journal Article
Open access
PDF file
ASAyman Al Saati
Ayman Al Saati
PPPierre Vande Perre
Pierre Vande Perre
JPJulien Plenecassagnes
Julien Plenecassagnes
JGJulia Gilhodes
Julia Gilhodes
NMNils Monselet
Nils Monselet
CTChristine Toulas
Christine Toulas
Even though male breast cancer (MBC) risk encompasses both genetic and environmental aetiologies, the primary risk factor is a germline pathogenic variant (PV) or likely pathogenic variant (LPV) in BRCA2, BRCA1 and/or PALB2 genes. To identify new potential MBC-specific predisposition genes, we sequenced a panel of 585 carcinogenesis genes in an MBC cohort without BRCA1/BRCA2/PALB2 PV/LPV. We identified 14 genes carrying rare PVs/LPVs in the MBC population versus noncancer non-Finnish European men, predominantly coding for DNA repair and maintenance of genomic stability proteins. We identified for the first time PVs/LPVs in PRCC (pre-mRNA processing), HOXA9 (transcription regulation), RECQL4 and WRN (maintenance of genomic stability) as well as in genes involved in other cellular processes. To study the specificity of this MBC PV/LPV profile, we examined whether variants in the same genes could be detected in a female breast cancer (FBC) cohort without BRCA1/BRCA2/PALB2 PV/LPV. Only 5/109 women (4.6%) carried a PV/LPV versus 18/85 men (21.2%) on these genes. FBC did not carry any PV/LPV on 11 of these genes. Although 5.9% of the MBC cohort carried PVs/LPVs in PALLD and ERCC2, neither of these genes were altered in our FBC cohort. Our data suggest that in addition to BRCA1/BRCA2/PALB2, other genes involved in DNA repair/maintenance or genomic stability as well as cell adhesion may form a specific MBC PV/LPV signature.